Naturewise Biotech & Medicals (ROCO:4732) Stock Based Compensation: NT$1.6 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4732 Naturewise Biotech & Medicals Corp ROCO:4732
57 GF Score
Price NT$15.90
GF Value NT$22.04
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Naturewise Biotech & Medicals Stock Based Compensation?

Naturewise Biotech & Medicals ROCO:4732 +4.26% 57 Stock Based Compensation is NT$1.6 Mil as of Dec. 2025. GuruFocus rates ROCO:4732 with a GF Score™ of 57/100 and a GF Value™ of NT$22.04 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Naturewise Biotech & Medicals's Stock Based Compensation for the six months ended in Dec. 2025 was NT$1.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.6 Mil.

Naturewise Biotech & Medicals Stock Based Compensation Related Terms

Naturewise Biotech & Medicals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Naturewise Biotech & Medicals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturewise Biotech & Medicals Stock Based Compensation Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.71 6.83 5.78 1.60

Naturewise Biotech & Medicals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.41 3.17 2.61 0.62 0.98
ROCO:4732
57GF Score
Naturewise Biotech & Medicals Corp ROCO:4732
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturewise Biotech & Medicals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$1.6 Mil.

What does a Stock Based Compensation of NT$1.6 Mil mean?
Naturewise Biotech & Medicals (ROCO:4732) has a Stock Based Compensation of NT$1.6 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Naturewise Biotech & Medicals and its competitors.
Is Naturewise Biotech & Medicals' Stock Based Compensation too high?
Naturewise Biotech & Medicals' current Stock Based Compensation is NT$1.6 Mil. Overall, Naturewise Biotech & Medicals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Stock Based Compensation compare to VRTX and REGN?
Naturewise Biotech & Medicals' Stock Based Compensation of NT$1.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Naturewise Biotech & Medicals and its competitors. Naturewise Biotech & Medicals's current Stock Based Compensation is NT$1.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.04, compared to a current price of NT$15.90 — trading 27.9% below its estimated fair value. The current Stock Based Compensation is NT$1.6 Mil. Naturewise Biotech & Medicals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Stock Based Compensation is NT$1.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?

Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued. The current stock price of NT$15.90 is trading 27.9% below its estimated GF Value™ of NT$22.04. GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.

Key valuation signals for ROCO:4732:

  • Stock Based Compensation: NT$1.6 Mil
  • GF Value™: NT$22.04 vs. price of NT$15.90 (27.9% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Naturewise Biotech & Medicals Business Description

Address No. 36, Bade Road, 6th Floor, Section 3, Songshan District, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
57GF Score

Get the complete analysis for ROCO:4732

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.90
Price
NT$22.04
GF Value